Biopsy Guidance Systems Market (2026 - 2033)

Biopsy Guidance Systems Market Summary

The global biopsy guidance systems market size was valued at USD 1.2 billion in 2025 and is projected to grow from USD 1.3 billion in 2026 to USD 1.9 billion in 2033, at a CAGR of 6.1% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 42.0% in 2025. The growth of the market is supported by the expanding geriatric population, rising incidence of cancer worldwide, increasing preference for minimally invasive procedures, and continuous advancements in medical imaging technologies. Growing adoption of three-dimensional (3D) imaging and image-guided biopsy procedures is further supporting demand for biopsy guidance systems.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

The rising prevalence of cancer is a key factor expected to drive market growth during the forecast period. According to the American Cancer Society, in 2025, approximately 2,041,910 new cancer cases and 618,120 cancer deaths are projected in the U.S. The increasing number of cancer diagnoses is driving demand for early diagnostic procedures, including image-guided biopsies, supporting the adoption of biopsy guidance systems.

Government initiatives and awareness campaigns led by non-governmental organizations are further supporting cancer screening and early diagnosis. Breast cancer remains one of the most commonly diagnosed cancers worldwide and a major cause of cancer-related mortality among women. In October 2024, the World Health Organization (WHO) conducted its Global Breast Cancer Initiative (GBCI) Breast Cancer Awareness Month campaign under the theme "No one should face breast cancer alone," with a focus on promoting breast cancer screening, early detection, and timely diagnosis. These initiatives contribute to increased screening activities and diagnostic procedures, supporting demand for biopsy guidance systems.

Analyst Perspective

The biopsy guidance systems industry is witnessing steady growth as healthcare providers increasingly prioritize early and accurate disease diagnosis. Rising adoption of minimally invasive biopsy procedures, combined with continuous improvements in imaging technologies such as ultrasound, MRI, CT, and stereotactic guidance, is enhancing procedural accuracy and clinical outcomes. Hospitals and diagnostic centers are also investing in advanced image-guided systems to improve workflow efficiency and reduce procedure-related complications. In addition, the growing burden of cancer and increasing screening programs are creating sustained demand for biopsy procedures worldwide. Technological innovations that improve lesion visualization, targeting precision, and real-time guidance are expected to support product adoption. Overall, the market is expected to grow steadily, supported by ongoing advances in diagnostic imaging and precision medicine.

Product Insights

By product, the stereotactic-guided biopsy segment held the largest market share, at around 39.0%, in 2025. The segment dominated the market owing to the growing preference for minimally invasive biopsy procedures, which are associated with shorter recovery times, reduced tissue trauma, and minimal scarring. Stereotactic-guided biopsy is particularly effective for evaluating small or non-palpable breast lesions that are not clearly visible on ultrasound, improving diagnostic accuracy. Continued advancements in automated core biopsy devices have further supported the adoption of stereotactic-guided biopsy systems.

The ultrasound-guided biopsy section is expected to register the fastest CAGR during the forecast period. Ultrasound is widely used as a real-time imaging modality to guide percutaneous biopsies and fine-needle aspiration procedures for abdominal, pelvic, thyroid, breast, and soft-tissue lesions. The technology offers several advantages, including portability, lower procedural costs, and the absence of ionizing radiation compared with CT-guided biopsy. These benefits, combined with growing preference for minimally invasive image-guided procedures, continue to support the adoption of ultrasound-guided biopsy systems.

End Use Insights

By end use, the hospitals segment accounted for over 38.0% of the market in 2025. The segment dominated due to the high volume of image-guided biopsy procedures performed in hospitals, supported by advanced diagnostic imaging infrastructure, the availability of multidisciplinary clinical teams, and increasing cancer diagnosis rates. Hospitals remain the primary setting for complex biopsy procedures requiring integrated imaging and pathology services. In February 2026, Paras Health reported that more than 20,000 new cancer patients were diagnosed and treated across its hospital network, reflecting the growing demand for oncology diagnostic services and image-guided biopsy procedures. The increasing burden of cancer and continued investment in advanced diagnostic technologies are supporting demand for biopsy guidance systems in hospitals.

The specialty clinics segment is expected to register a significant growth rate during the forecast period. Rising preference for outpatient care, minimally invasive procedures, and specialized cancer diagnosis is driving patient visits to specialty clinics. These facilities increasingly adopt advanced biopsy guidance systems to improve diagnostic accuracy and procedural efficiency while reducing procedure time and hospital stays. Growing investments in dedicated oncology, breast care, and interventional radiology clinics are further supporting the adoption of image-guided biopsy technologies across specialty healthcare settings.

Application Insights

By application, the brain biopsy segment accounted for over 42.0% of the biopsy guidance systems market in 2025, driven by the rising prevalence of brain tumors and neurological disorders that require tissue diagnosis. Growing adoption of stereotactic biopsy procedures, supported by advancements in image-guided navigation technologies, is improving procedural precision and diagnostic accuracy. According to the study titled "Stereotactic Biopsy in Patients with Presumed Brain Metastases Alters Treatment Trajectory", published in Neuro-Oncology Advances in 2026, the study reported that stereotactic brain biopsy achieved a diagnostic yield of 94.7% with no major procedural complications in patients with suspected brain metastases, underscoring its value as a reliable diagnostic tool when surgical resection is not achievable.

The breast biopsy segment is expected to register the fastest CAGR over the forecast period. Rising breast cancer incidence, increasing participation in breast cancer screening programs, and growing preference for minimally invasive diagnostic procedures are driving segment growth. Advancements in ultrasound-, stereotactic-, and MRI-guided biopsy techniques are improving lesion targeting and procedural accuracy, supporting broader adoption across hospitals and specialty diagnostic centers.

Regional Insights

North America biopsy guidance systems dominated the market, accounting for a revenue share of 42.0% of revenue in 2025. Market growth is driven by the expanding adoption of image-guided biopsy procedures, rising cancer incidence, increasing investments in oncology research, and continuous advancements in diagnostic imaging technologies. Growing investments by government organizations, research institutes, pharmaceutical companies, and healthcare providers in cancer diagnosis and precision medicine are further supporting market expansion.

To learn more about this report, Download Free Sample Report

U.S. Biopsy Guidance Systems Market Trends

The U.S. biopsy guidance system industry is expected to experience growth during the forecast period. Growth is supported by the rising incidence of cancer, expanding oncology care infrastructure, and increasing adoption of advanced image-guided biopsy technologies. According to the Barbara Ann Karmanos Cancer Institute, in 2026, the institute treated around 15,754 new cancer cases, representing an increase of more than 47% compared with 2020. The increasing number of cancer patients is driving demand for oncology diagnostic services, including image-guided biopsy procedures.

Europe Biopsy Guidance Systems Market Trends

The Europe biopsy guidance system industry is expected to grow significantly during the forecast period. Rising cancer incidence, increasing awareness regarding early diagnosis, expanding specialty cancer care services, and continued investments in diagnostic infrastructure are supporting market growth. Growing adoption of minimally invasive diagnostic procedures is further increasing demand for biopsy guidance systems across the region.

The UK biopsy guidance system industry held the largest revenue share in the regional industry. Growth is supported by improvements in healthcare infrastructure and National Health Service (NHS) initiatives to expand diagnostic capacity and improve early cancer detection. According to the UK Government, in March 2024, the Community Diagnostic Centers delivered more than 7 million tests, checks, and scans across England through a network of 155 centers. The expansion of diagnostic services is increasing access to cancer diagnosis and supporting demand for biopsy guidance systems.

Asia Pacific Biopsy Guidance Systems Market Trends

The biopsy-guided systems industry in the Asia Pacific is expected to experience the fastest CAGR during the forecast period. Market growth is supported by the increasing incidence of cancer, expanding healthcare infrastructure, rising adoption of advanced diagnostic imaging technologies, and growing investments in oncology care. Government initiatives promoting cancer screening and early diagnosis are further supporting the adoption of biopsy guidance systems across the region.

The China biopsy guidance systems industry accounted for a significant revenue share in 2025. Growth is supported by increasing adoption of magnetic resonance imaging (MRI), ultrasound-guided biopsy, computed tomography (CT)-guided biopsy, and robotic-assisted biopsy technologies. Government initiatives promoting cancer screening, continued investment in healthcare infrastructure, and expanding access to advanced diagnostic services are further supporting the adoption of biopsy guidance systems across the country.

Key Biopsy Guidance Systems Company Insights

The biopsy guidance systems industry is characterized by established medical device manufacturers focusing on product innovation, strategic collaborations, acquisitions, and research and development to strengthen their biopsy imaging and guidance portfolios. Companies are expanding the use of advanced imaging technologies and minimally invasive biopsy solutions to improve diagnostic accuracy and procedural efficiency across oncology applications.

Key Biopsy Guidance Systems Companies:

The following key companies have been profiled for this study on the biopsy guidance systems market:

• Becton, Dickinson, and Company

• Hologic, Inc.

• B. Braun Melsungen AG

• ARGON MEDICAL

• Boston Scientific Corporation

• INRAD Inc.

• Cook Medical

• PLANMED OY

Recent Developments

• In April 2025, Koelis partnered with Bot Image to integrate the Trinity MRI fusion-guided biopsy platform with the FDA-cleared ProstatID artificial intelligence software for prostate cancer detection and diagnosis. The collaboration is designed to improve prostate biopsy accuracy and clinical workflow efficiency.

• In February 2025, Limaca Medical launched Precision-GI in the U.S., an automated, motorized endoscopic ultrasound-guided biopsy device for gastrointestinal tissue sampling. The device is designed to standardize endoscopic ultrasound-guided biopsy procedures and improve tissue sample collection in the diagnosis of gastrointestinal cancer.

• In July 2024, Stryker acquired MOLLI Surgical, a developer of wire-free soft tissue localization technology used in breast-conserving surgery. The acquisition expands Stryker's breast cancer care portfolio by adding localization technology used before breast lesion excision procedures.

• In April 2024, GE HealthCare completed the acquisition of MIM Software to expand its capabilities in imaging workflows across oncology, cardiology, neurology, and urology. The acquisition strengthens GE HealthCare's precision care portfolio by integrating advanced imaging analysis and artificial intelligence capabilities into its healthcare solutions.

Biopsy Guidance Systems Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global biopsy guidance system market report based on product, application, end use, and region:

• Product Outlook (Revenue, USD Billion, 2021 - 2033)

  • Stereotactic Guided Biopsy

  • Ultrasound Guided Biopsy

  • MRI Guided Biopsy

• Application Outlook (Revenue, USD Billion, 2021 - 2033)

  • Brain Biopsy

  • Breast Biopsy

  • Others

• End Use Outlook (Revenue, USD Billion, 2021 - 2033)

  • Hospitals

  • Specialty Clinics

  • Diagnostic Centers

  • Research and Academic Institutes

• Regional Outlook (Revenue, USD Billion, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait